Key regions: Germany, India, United Kingdom, China, Canada
The demand for oncology drugs in Ireland has been steadily increasing over the years, with a significant rise in recent times due to various factors.
Customer preferences: Cancer is one of the leading causes of death in Ireland, and the rising incidence of the disease has led to an increase in demand for oncology drugs. Patients and healthcare professionals in Ireland are increasingly seeking newer and more effective treatments that can improve outcomes and quality of life for cancer patients.
Trends in the market: The oncology drugs market in Ireland is witnessing a shift towards targeted therapies and immunotherapies, which are more precise and have fewer side effects than traditional chemotherapy. The market is also seeing an increase in the number of biosimilars, which are cheaper versions of biologic drugs that have lost their patent protection.Another trend in the market is the increasing use of combination therapies, where two or more drugs are used together to improve treatment outcomes. This approach is particularly effective in treating cancers that have become resistant to single-agent therapies.
Local special circumstances: The Irish government has implemented a number of initiatives to improve access to oncology drugs, including the establishment of a Cancer Drugs Access Programme (CDAP) in 2017. The CDAP aims to provide patients with access to new and innovative cancer treatments, including oncology drugs that are not yet approved for reimbursement by the Health Service Executive (HSE).
Underlying macroeconomic factors: The Irish economy has been growing steadily in recent years, which has led to an increase in healthcare spending. The government has also made a commitment to increase funding for cancer services, which is expected to drive growth in the oncology drugs market.In conclusion, the oncology drugs market in Ireland is evolving rapidly, with a shift towards targeted therapies, immunotherapies, and combination therapies. The Irish government's initiatives to improve access to cancer treatments are also expected to drive growth in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
